Bio-Rad Laboratories, Inc. (NYSE: BIO) Stock Competitors & Peer Comparison
See BIO's competitors and their performance on the NYSE and across the wider stock market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for BIO and its NYSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| BIO | $356.25 | +0.48% | 9.6B | 38.40 | $9.28 | N/A |
| ABT | $109.72 | +1.01% | 189.9B | 21.06 | $5.21 | +2.26% |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| SYK | $348.15 | +0.68% | 133.4B | 25.99 | $13.39 | +1.00% |
| MDT | $90.68 | +1.42% | 116B | 16.39 | $5.53 | +3.15% |
| BSX | $51.19 | +1.45% | 76.1B | 16.51 | $3.10 | N/A |
| EW | $93.66 | +1.77% | 53.9B | 34.69 | $2.70 | N/A |
| DXCM | $89.53 | +2.14% | 33.8B | 38.42 | $2.33 | N/A |
| RMD | $224.84 | +2.18% | 32.6B | 20.87 | $10.77 | +1.07% |
| PHG | $27.05 | +0.41% | 26.4B | 15.46 | $1.75 | +3.65% |
Stock Comparison
Abbott Laboratories (NYSE: ABT)
BIO vs ABT Comparison August 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 9.6B. In comparison, ABT has a market cap of 189.9B. Regarding current trading prices, BIO is priced at $356.25 on the NYSE, while ABT trades at $109.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of 38.40, whereas ABT's P/E ratio is 21.06. In terms of profitability, BIO's ROE is +0.03%, compared to ABT's ROE of +0.11%. Regarding short-term risk, BIO is more volatile compared to ABT. This indicates higher risk in terms of short-term price fluctuations for BIO.Check ABT's competition here
Boston Scientific Corporation (NYSE: BSX-PA)
BIO vs BSX-PA Comparison August 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 9.6B. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, BIO is priced at $356.25 on the NYSE, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of 38.40, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, BIO's ROE is +0.03%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, BIO is less volatile compared to BSX-PA. This indicates lower risk in terms of short-term price fluctuations for BIO.Check BSX-PA's competition here
Stryker Corporation (NYSE: SYK)
BIO vs SYK Comparison August 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 9.6B. In comparison, SYK has a market cap of 133.4B. Regarding current trading prices, BIO is priced at $356.25 on the NYSE, while SYK trades at $348.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of 38.40, whereas SYK's P/E ratio is 25.99. In terms of profitability, BIO's ROE is +0.03%, compared to SYK's ROE of +0.16%. Regarding short-term risk, BIO is more volatile compared to SYK. This indicates higher risk in terms of short-term price fluctuations for BIO.Check SYK's competition here
Medtronic plc (NYSE: MDT)
BIO vs MDT Comparison August 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 9.6B. In comparison, MDT has a market cap of 116B. Regarding current trading prices, BIO is priced at $356.25 on the NYSE, while MDT trades at $90.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of 38.40, whereas MDT's P/E ratio is 16.39. In terms of profitability, BIO's ROE is +0.03%, compared to MDT's ROE of +0.10%. Regarding short-term risk, BIO is more volatile compared to MDT. This indicates higher risk in terms of short-term price fluctuations for BIO.Check MDT's competition here
Boston Scientific Corporation (NYSE: BSX)
BIO vs BSX Comparison August 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 9.6B. In comparison, BSX has a market cap of 76.1B. Regarding current trading prices, BIO is priced at $356.25 on the NYSE, while BSX trades at $51.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of 38.40, whereas BSX's P/E ratio is 16.51. In terms of profitability, BIO's ROE is +0.03%, compared to BSX's ROE of +0.15%. Regarding short-term risk, BIO is less volatile compared to BSX. This indicates lower risk in terms of short-term price fluctuations for BIO.Check BSX's competition here
Edwards Lifesciences Corporation (NYSE: EW)
BIO vs EW Comparison August 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 9.6B. In comparison, EW has a market cap of 53.9B. Regarding current trading prices, BIO is priced at $356.25 on the NYSE, while EW trades at $93.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of 38.40, whereas EW's P/E ratio is 34.69. In terms of profitability, BIO's ROE is +0.03%, compared to EW's ROE of +0.10%. Regarding short-term risk, BIO is more volatile compared to EW. This indicates higher risk in terms of short-term price fluctuations for BIO.Check EW's competition here
DexCom, Inc. (NASDAQ: DXCM)
BIO vs DXCM Comparison August 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 9.6B. In comparison, DXCM has a market cap of 33.8B. Regarding current trading prices, BIO is priced at $356.25 on the NYSE, while DXCM trades at $89.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of 38.40, whereas DXCM's P/E ratio is 38.42. In terms of profitability, BIO's ROE is +0.03%, compared to DXCM's ROE of +0.36%. Regarding short-term risk, BIO is less volatile compared to DXCM. This indicates lower risk in terms of short-term price fluctuations for BIO.Check DXCM's competition here
ResMed Inc. (NYSE: RMD)
BIO vs RMD Comparison August 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 9.6B. In comparison, RMD has a market cap of 32.6B. Regarding current trading prices, BIO is priced at $356.25 on the NYSE, while RMD trades at $224.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of 38.40, whereas RMD's P/E ratio is 20.87. In terms of profitability, BIO's ROE is +0.03%, compared to RMD's ROE of +0.24%. Regarding short-term risk, BIO is less volatile compared to RMD. This indicates lower risk in terms of short-term price fluctuations for BIO.Check RMD's competition here
Koninklijke Philips N.V. (NYSE: PHG)
BIO vs PHG Comparison August 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 9.6B. In comparison, PHG has a market cap of 26.4B. Regarding current trading prices, BIO is priced at $356.25 on the NYSE, while PHG trades at $27.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of 38.40, whereas PHG's P/E ratio is 15.46. In terms of profitability, BIO's ROE is +0.03%, compared to PHG's ROE of +0.10%. Regarding short-term risk, BIO is more volatile compared to PHG. This indicates higher risk in terms of short-term price fluctuations for BIO.Check PHG's competition here
Zimmer Biomet Holdings, Inc. (NYSE: ZBH)
BIO vs ZBH Comparison August 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 9.6B. In comparison, ZBH has a market cap of 18.8B. Regarding current trading prices, BIO is priced at $356.25 on the NYSE, while ZBH trades at $97.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of 38.40, whereas ZBH's P/E ratio is 11.46. In terms of profitability, BIO's ROE is +0.03%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, BIO is more volatile compared to ZBH. This indicates higher risk in terms of short-term price fluctuations for BIO.Check ZBH's competition here
Abiomed, Inc. (NASDAQ: ABMD)
BIO vs ABMD Comparison August 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 9.6B. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, BIO is priced at $356.25 on the NYSE, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of 38.40, whereas ABMD's P/E ratio is 65.36. In terms of profitability, BIO's ROE is +0.03%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, BIO is more volatile compared to ABMD. This indicates higher risk in terms of short-term price fluctuations for BIO.Check ABMD's competition here
Penumbra, Inc. (NYSE: PEN)
BIO vs PEN Comparison August 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 9.6B. In comparison, PEN has a market cap of 12.9B. Regarding current trading prices, BIO is priced at $356.25 on the NYSE, while PEN trades at $326.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of 38.40, whereas PEN's P/E ratio is 85.23. In terms of profitability, BIO's ROE is +0.03%, compared to PEN's ROE of +0.11%. Regarding short-term risk, BIO is more volatile compared to PEN. This indicates higher risk in terms of short-term price fluctuations for BIO.Check PEN's competition here
Smith & Nephew plc (NYSE: SNN)
BIO vs SNN Comparison August 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 9.6B. In comparison, SNN has a market cap of 12.6B. Regarding current trading prices, BIO is priced at $356.25 on the NYSE, while SNN trades at $30.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of 38.40, whereas SNN's P/E ratio is 14.12. In terms of profitability, BIO's ROE is +0.03%, compared to SNN's ROE of +0.12%. Regarding short-term risk, BIO is more volatile compared to SNN. This indicates higher risk in terms of short-term price fluctuations for BIO.Check SNN's competition here
ShockWave Medical, Inc. (NASDAQ: SWAV)
BIO vs SWAV Comparison August 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 9.6B. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, BIO is priced at $356.25 on the NYSE, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of 38.40, whereas SWAV's P/E ratio is 78.76. In terms of profitability, BIO's ROE is +0.03%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, BIO is more volatile compared to SWAV. This indicates higher risk in terms of short-term price fluctuations for BIO.Check SWAV's competition here
Align Technology, Inc. (NASDAQ: ALGN)
BIO vs ALGN Comparison August 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 9.6B. In comparison, ALGN has a market cap of 12.4B. Regarding current trading prices, BIO is priced at $356.25 on the NYSE, while ALGN trades at $172.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of 38.40, whereas ALGN's P/E ratio is 15.77. In terms of profitability, BIO's ROE is +0.03%, compared to ALGN's ROE of +0.14%. Regarding short-term risk, BIO is less volatile compared to ALGN. This indicates lower risk in terms of short-term price fluctuations for BIO.Check ALGN's competition here
Globus Medical, Inc. (NYSE: GMED)
BIO vs GMED Comparison August 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 9.6B. In comparison, GMED has a market cap of 11.5B. Regarding current trading prices, BIO is priced at $356.25 on the NYSE, while GMED trades at $85.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of 38.40, whereas GMED's P/E ratio is 19.17. In terms of profitability, BIO's ROE is +0.03%, compared to GMED's ROE of +0.12%. Regarding short-term risk, BIO is more volatile compared to GMED. This indicates higher risk in terms of short-term price fluctuations for BIO.Check GMED's competition here
Glaukos Corporation (NYSE: GKOS)
BIO vs GKOS Comparison August 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 9.6B. In comparison, GKOS has a market cap of 10.7B. Regarding current trading prices, BIO is priced at $356.25 on the NYSE, while GKOS trades at $182.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of 38.40, whereas GKOS's P/E ratio is -211.72. In terms of profitability, BIO's ROE is +0.03%, compared to GKOS's ROE of -0.27%. Regarding short-term risk, BIO is less volatile compared to GKOS. This indicates lower risk in terms of short-term price fluctuations for BIO.Check GKOS's competition here
Insulet Corp. (NASDAQ: PODD)
BIO vs PODD Comparison August 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 9.6B. In comparison, PODD has a market cap of 10B. Regarding current trading prices, BIO is priced at $356.25 on the NYSE, while PODD trades at $144.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of 38.40, whereas PODD's P/E ratio is 24.65. In terms of profitability, BIO's ROE is +0.03%, compared to PODD's ROE of +0.27%. Regarding short-term risk, BIO is less volatile compared to PODD. This indicates lower risk in terms of short-term price fluctuations for BIO.Check PODD's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO-B)
BIO vs BIO-B Comparison August 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 9.6B. In comparison, BIO-B has a market cap of 9.5B. Regarding current trading prices, BIO is priced at $356.25 on the NYSE, while BIO-B trades at $348.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of 38.40, whereas BIO-B's P/E ratio is 103.33. In terms of profitability, BIO's ROE is +0.03%, compared to BIO-B's ROE of +0.03%. Regarding short-term risk, BIO is more volatile compared to BIO-B. This indicates higher risk in terms of short-term price fluctuations for BIO.Check BIO-B's competition here
Masimo Corporation (NASDAQ: MASI)
BIO vs MASI Comparison August 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 9.6B. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, BIO is priced at $356.25 on the NYSE, while MASI trades at $179.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of 38.40, whereas MASI's P/E ratio is 44.43. In terms of profitability, BIO's ROE is +0.03%, compared to MASI's ROE of +0.09%. Regarding short-term risk, BIO is more volatile compared to MASI. This indicates higher risk in terms of short-term price fluctuations for BIO.Check MASI's competition here
Bruker Corporation (NASDAQ: BRKR)
BIO vs BRKR Comparison August 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 9.6B. In comparison, BRKR has a market cap of 8.7B. Regarding current trading prices, BIO is priced at $356.25 on the NYSE, while BRKR trades at $57.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of 38.40, whereas BRKR's P/E ratio is 28.65. In terms of profitability, BIO's ROE is +0.03%, compared to BRKR's ROE of -0.03%. Regarding short-term risk, BIO is less volatile compared to BRKR. This indicates lower risk in terms of short-term price fluctuations for BIO.Check BRKR's competition here
Inari Medical, Inc. (NASDAQ: NARI)
BIO vs NARI Comparison August 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 9.6B. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, BIO is priced at $356.25 on the NYSE, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of 38.40, whereas NARI's P/E ratio is -59.24. In terms of profitability, BIO's ROE is +0.03%, compared to NARI's ROE of -0.00%. Regarding short-term risk, BIO is more volatile compared to NARI. This indicates higher risk in terms of short-term price fluctuations for BIO.Check NARI's competition here
LivaNova PLC (NASDAQ: LIVN)
BIO vs LIVN Comparison August 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 9.6B. In comparison, LIVN has a market cap of 4.3B. Regarding current trading prices, BIO is priced at $356.25 on the NYSE, while LIVN trades at $78.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of 38.40, whereas LIVN's P/E ratio is 18.67. In terms of profitability, BIO's ROE is +0.03%, compared to LIVN's ROE of +0.15%. Regarding short-term risk, BIO is less volatile compared to LIVN. This indicates lower risk in terms of short-term price fluctuations for BIO.Check LIVN's competition here
Integer Holdings Corporation (NYSE: ITGR)
BIO vs ITGR Comparison August 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 9.6B. In comparison, ITGR has a market cap of 4.2B. Regarding current trading prices, BIO is priced at $356.25 on the NYSE, while ITGR trades at $125.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of 38.40, whereas ITGR's P/E ratio is 19.69. In terms of profitability, BIO's ROE is +0.03%, compared to ITGR's ROE of +0.07%. Regarding short-term risk, BIO is more volatile compared to ITGR. This indicates higher risk in terms of short-term price fluctuations for BIO.Check ITGR's competition here
iRhythm Technologies, Inc. (NASDAQ: IRTC)
BIO vs IRTC Comparison August 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 9.6B. In comparison, IRTC has a market cap of 4B. Regarding current trading prices, BIO is priced at $356.25 on the NYSE, while IRTC trades at $121.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of 38.40, whereas IRTC's P/E ratio is -190.42. In terms of profitability, BIO's ROE is +0.03%, compared to IRTC's ROE of -0.09%. Regarding short-term risk, BIO is less volatile compared to IRTC. This indicates lower risk in terms of short-term price fluctuations for BIO.Check IRTC's competition here
Haemonetics Corporation (NYSE: HAE)
BIO vs HAE Comparison August 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 9.6B. In comparison, HAE has a market cap of 4B. Regarding current trading prices, BIO is priced at $356.25 on the NYSE, while HAE trades at $87.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of 38.40, whereas HAE's P/E ratio is 17.42. In terms of profitability, BIO's ROE is +0.03%, compared to HAE's ROE of +0.11%. Regarding short-term risk, BIO is less volatile compared to HAE. This indicates lower risk in terms of short-term price fluctuations for BIO.Check HAE's competition here
Axonics, Inc. (NASDAQ: AXNX)
BIO vs AXNX Comparison August 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 9.6B. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, BIO is priced at $356.25 on the NYSE, while AXNX trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of 38.40, whereas AXNX's P/E ratio is -709.80. In terms of profitability, BIO's ROE is +0.03%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, BIO is more volatile compared to AXNX. This indicates higher risk in terms of short-term price fluctuations for BIO.Check AXNX's competition here
TransMedics Group, Inc. (NASDAQ: TMDX)
BIO vs TMDX Comparison August 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 9.6B. In comparison, TMDX has a market cap of 3.1B. Regarding current trading prices, BIO is priced at $356.25 on the NYSE, while TMDX trades at $89.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of 38.40, whereas TMDX's P/E ratio is 45.36. In terms of profitability, BIO's ROE is +0.03%, compared to TMDX's ROE of +0.33%. Regarding short-term risk, BIO is less volatile compared to TMDX. This indicates lower risk in terms of short-term price fluctuations for BIO.Check TMDX's competition here
AxoGen, Inc. (NASDAQ: AXGN)
BIO vs AXGN Comparison August 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 9.6B. In comparison, AXGN has a market cap of 2.6B. Regarding current trading prices, BIO is priced at $356.25 on the NYSE, while AXGN trades at $48.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of 38.40, whereas AXGN's P/E ratio is 127.58. In terms of profitability, BIO's ROE is +0.03%, compared to AXGN's ROE of -0.18%. Regarding short-term risk, BIO is less volatile compared to AXGN. This indicates lower risk in terms of short-term price fluctuations for BIO.Check AXGN's competition here
Butterfly Network, Inc. (NYSE: BFLY)
BIO vs BFLY Comparison August 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 9.6B. In comparison, BFLY has a market cap of 2.5B. Regarding current trading prices, BIO is priced at $356.25 on the NYSE, while BFLY trades at $9.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of 38.40, whereas BFLY's P/E ratio is -39.02. In terms of profitability, BIO's ROE is +0.03%, compared to BFLY's ROE of -0.38%. Regarding short-term risk, BIO is less volatile compared to BFLY. This indicates lower risk in terms of short-term price fluctuations for BIO.Check BFLY's competition here
UFP Technologies, Inc. (NASDAQ: UFPT)
BIO vs UFPT Comparison August 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 9.6B. In comparison, UFPT has a market cap of 2.5B. Regarding current trading prices, BIO is priced at $356.25 on the NYSE, while UFPT trades at $321.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of 38.40, whereas UFPT's P/E ratio is 32.88. In terms of profitability, BIO's ROE is +0.03%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, BIO is less volatile compared to UFPT. This indicates lower risk in terms of short-term price fluctuations for BIO.Check UFPT's competition here
Establishment Labs Holdings Inc. (NASDAQ: ESTA)
BIO vs ESTA Comparison August 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 9.6B. In comparison, ESTA has a market cap of 2.2B. Regarding current trading prices, BIO is priced at $356.25 on the NYSE, while ESTA trades at $74.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of 38.40, whereas ESTA's P/E ratio is -58.95. In terms of profitability, BIO's ROE is +0.03%, compared to ESTA's ROE of -2.04%. Regarding short-term risk, BIO is less volatile compared to ESTA. This indicates lower risk in terms of short-term price fluctuations for BIO.Check ESTA's competition here
NuVasive, Inc. (NASDAQ: NUVA)
BIO vs NUVA Comparison August 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 9.6B. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, BIO is priced at $356.25 on the NYSE, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of 38.40, whereas NUVA's P/E ratio is 75.00. In terms of profitability, BIO's ROE is +0.03%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, BIO is less volatile compared to NUVA. This indicates lower risk in terms of short-term price fluctuations for BIO.Check NUVA's competition here
Novocure Ltd (NASDAQ: NVCR)
BIO vs NVCR Comparison August 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 9.6B. In comparison, NVCR has a market cap of 2.1B. Regarding current trading prices, BIO is priced at $356.25 on the NYSE, while NVCR trades at $17.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of 38.40, whereas NVCR's P/E ratio is -11.54. In terms of profitability, BIO's ROE is +0.03%, compared to NVCR's ROE of -0.44%. Regarding short-term risk, BIO is less volatile compared to NVCR. This indicates lower risk in terms of short-term price fluctuations for BIO.Check NVCR's competition here
Inspire Medical Systems, Inc. (NYSE: INSP)
BIO vs INSP Comparison August 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 9.6B. In comparison, INSP has a market cap of 1.7B. Regarding current trading prices, BIO is priced at $356.25 on the NYSE, while INSP trades at $59.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of 38.40, whereas INSP's P/E ratio is 26.07. In terms of profitability, BIO's ROE is +0.03%, compared to INSP's ROE of +0.18%. Regarding short-term risk, BIO is less volatile compared to INSP. This indicates lower risk in terms of short-term price fluctuations for BIO.Check INSP's competition here
Tandem Diabetes Care, Inc. (NASDAQ: TNDM)
BIO vs TNDM Comparison August 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 9.6B. In comparison, TNDM has a market cap of 1.6B. Regarding current trading prices, BIO is priced at $356.25 on the NYSE, while TNDM trades at $23.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of 38.40, whereas TNDM's P/E ratio is -21.31. In terms of profitability, BIO's ROE is +0.03%, compared to TNDM's ROE of -0.46%. Regarding short-term risk, BIO is less volatile compared to TNDM. This indicates lower risk in terms of short-term price fluctuations for BIO.Check TNDM's competition here
CONMED Corporation (NYSE: CNMD)
BIO vs CNMD Comparison August 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 9.6B. In comparison, CNMD has a market cap of 1.5B. Regarding current trading prices, BIO is priced at $356.25 on the NYSE, while CNMD trades at $49.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of 38.40, whereas CNMD's P/E ratio is 10.89. In terms of profitability, BIO's ROE is +0.03%, compared to CNMD's ROE of +0.06%. Regarding short-term risk, BIO is more volatile compared to CNMD. This indicates higher risk in terms of short-term price fluctuations for BIO.Check CNMD's competition here
Alphatec Holdings, Inc. (NASDAQ: ATEC)
BIO vs ATEC Comparison August 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 9.6B. In comparison, ATEC has a market cap of 1.4B. Regarding current trading prices, BIO is priced at $356.25 on the NYSE, while ATEC trades at $9.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of 38.40, whereas ATEC's P/E ratio is -156.17. In terms of profitability, BIO's ROE is +0.03%, compared to ATEC's ROE of -8.19%. Regarding short-term risk, BIO is less volatile compared to ATEC. This indicates lower risk in terms of short-term price fluctuations for BIO.Check ATEC's competition here
Enovis Corporation (NYSE: ENOV)
BIO vs ENOV Comparison August 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 9.6B. In comparison, ENOV has a market cap of 1.4B. Regarding current trading prices, BIO is priced at $356.25 on the NYSE, while ENOV trades at $24.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of 38.40, whereas ENOV's P/E ratio is 7.05. In terms of profitability, BIO's ROE is +0.03%, compared to ENOV's ROE of -0.68%. Regarding short-term risk, BIO is less volatile compared to ENOV. This indicates lower risk in terms of short-term price fluctuations for BIO.Check ENOV's competition here
Artivion, Inc. (NYSE: AORT)
BIO vs AORT Comparison August 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 9.6B. In comparison, AORT has a market cap of 1.4B. Regarding current trading prices, BIO is priced at $356.25 on the NYSE, while AORT trades at $28.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of 38.40, whereas AORT's P/E ratio is 47.35. In terms of profitability, BIO's ROE is +0.03%, compared to AORT's ROE of -0.01%. Regarding short-term risk, BIO is less volatile compared to AORT. This indicates lower risk in terms of short-term price fluctuations for BIO.Check AORT's competition here
Integra LifeSciences Holdings Corporation (NASDAQ: IART)
BIO vs IART Comparison August 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 9.6B. In comparison, IART has a market cap of 1.4B. Regarding current trading prices, BIO is priced at $356.25 on the NYSE, while IART trades at $17.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of 38.40, whereas IART's P/E ratio is 7.36. In terms of profitability, BIO's ROE is +0.03%, compared to IART's ROE of -0.01%. Regarding short-term risk, BIO is less volatile compared to IART. This indicates lower risk in terms of short-term price fluctuations for BIO.Check IART's competition here
Heska Corporation (NASDAQ: HSKA)
BIO vs HSKA Comparison August 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 9.6B. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, BIO is priced at $356.25 on the NYSE, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of 38.40, whereas HSKA's P/E ratio is -62.49. In terms of profitability, BIO's ROE is +0.03%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, BIO is more volatile compared to HSKA. This indicates higher risk in terms of short-term price fluctuations for BIO.Check HSKA's competition here
PROCEPT BioRobotics Corporation (NASDAQ: PRCT)
BIO vs PRCT Comparison August 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 9.6B. In comparison, PRCT has a market cap of 1.3B. Regarding current trading prices, BIO is priced at $356.25 on the NYSE, while PRCT trades at $22.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of 38.40, whereas PRCT's P/E ratio is -11.80. In terms of profitability, BIO's ROE is +0.03%, compared to PRCT's ROE of -0.31%. Regarding short-term risk, BIO is less volatile compared to PRCT. This indicates lower risk in terms of short-term price fluctuations for BIO.Check PRCT's competition here
Avanos Medical, Inc. (NYSE: AVNS)
BIO vs AVNS Comparison August 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 9.6B. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, BIO is priced at $356.25 on the NYSE, while AVNS trades at $24.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of 38.40, whereas AVNS's P/E ratio is 27.77. In terms of profitability, BIO's ROE is +0.03%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, BIO is more volatile compared to AVNS. This indicates higher risk in terms of short-term price fluctuations for BIO.Check AVNS's competition here
IRadimed Corporation (NASDAQ: IRMD)
BIO vs IRMD Comparison August 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 9.6B. In comparison, IRMD has a market cap of 1.1B. Regarding current trading prices, BIO is priced at $356.25 on the NYSE, while IRMD trades at $88.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of 38.40, whereas IRMD's P/E ratio is 44.69. In terms of profitability, BIO's ROE is +0.03%, compared to IRMD's ROE of +0.23%. Regarding short-term risk, BIO is less volatile compared to IRMD. This indicates lower risk in terms of short-term price fluctuations for BIO.Check IRMD's competition here
Lumexa Imaging Holdings, Inc. Common Stock (NASDAQ: LMRI)
BIO vs LMRI Comparison August 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 9.6B. In comparison, LMRI has a market cap of 1.1B. Regarding current trading prices, BIO is priced at $356.25 on the NYSE, while LMRI trades at $11.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of 38.40, whereas LMRI's P/E ratio is -22.69. In terms of profitability, BIO's ROE is +0.03%, compared to LMRI's ROE of -0.06%. Regarding short-term risk, BIO is less volatile compared to LMRI. This indicates lower risk in terms of short-term price fluctuations for BIO.Check LMRI's competition here
Silk Road Medical, Inc (NASDAQ: SILK)
BIO vs SILK Comparison August 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 9.6B. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, BIO is priced at $356.25 on the NYSE, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of 38.40, whereas SILK's P/E ratio is -18.96. In terms of profitability, BIO's ROE is +0.03%, compared to SILK's ROE of -0.35%. Regarding short-term risk, BIO is more volatile compared to SILK. This indicates higher risk in terms of short-term price fluctuations for BIO.Check SILK's competition here
Paragon 28, Inc. (NYSE: FNA)
BIO vs FNA Comparison August 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 9.6B. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, BIO is priced at $356.25 on the NYSE, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of 38.40, whereas FNA's P/E ratio is -19.83. In terms of profitability, BIO's ROE is +0.03%, compared to FNA's ROE of -0.35%. Regarding short-term risk, BIO is more volatile compared to FNA. This indicates higher risk in terms of short-term price fluctuations for BIO.Check FNA's competition here
Bioventus Inc. (NASDAQ: BVS)
BIO vs BVS Comparison August 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 9.6B. In comparison, BVS has a market cap of 938.3M. Regarding current trading prices, BIO is priced at $356.25 on the NYSE, while BVS trades at $13.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of 38.40, whereas BVS's P/E ratio is 18.22. In terms of profitability, BIO's ROE is +0.03%, compared to BVS's ROE of +0.28%. Regarding short-term risk, BIO is more volatile compared to BVS. This indicates higher risk in terms of short-term price fluctuations for BIO.Check BVS's competition here
Anteris Technologies Global Corp. (NASDAQ: AVR)
BIO vs AVR Comparison August 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 9.6B. In comparison, AVR has a market cap of 891.6M. Regarding current trading prices, BIO is priced at $356.25 on the NYSE, while AVR trades at $9.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of 38.40, whereas AVR's P/E ratio is -4.11. In terms of profitability, BIO's ROE is +0.03%, compared to AVR's ROE of -1.24%. Regarding short-term risk, BIO is less volatile compared to AVR. This indicates lower risk in terms of short-term price fluctuations for BIO.Check AVR's competition here
InMode Ltd. (NASDAQ: INMD)
BIO vs INMD Comparison August 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 9.6B. In comparison, INMD has a market cap of 870.3M. Regarding current trading prices, BIO is priced at $356.25 on the NYSE, while INMD trades at $15.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of 38.40, whereas INMD's P/E ratio is 10.51. In terms of profitability, BIO's ROE is +0.03%, compared to INMD's ROE of +0.12%. Regarding short-term risk, BIO is more volatile compared to INMD. This indicates higher risk in terms of short-term price fluctuations for BIO.Check INMD's competition here
Cardiovascular Systems, Inc. (NASDAQ: CSII)
BIO vs CSII Comparison August 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 9.6B. In comparison, CSII has a market cap of 844M. Regarding current trading prices, BIO is priced at $356.25 on the NYSE, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of 38.40, whereas CSII's P/E ratio is -20.83. In terms of profitability, BIO's ROE is +0.03%, compared to CSII's ROE of -0.14%. Regarding short-term risk, BIO is more volatile compared to CSII. This indicates higher risk in terms of short-term price fluctuations for BIO.Check CSII's competition here
SI-BONE, Inc. (NASDAQ: SIBN)
BIO vs SIBN Comparison August 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 9.6B. In comparison, SIBN has a market cap of 833.8M. Regarding current trading prices, BIO is priced at $356.25 on the NYSE, while SIBN trades at $18.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of 38.40, whereas SIBN's P/E ratio is -55.29. In terms of profitability, BIO's ROE is +0.03%, compared to SIBN's ROE of -0.08%. Regarding short-term risk, BIO is less volatile compared to SIBN. This indicates lower risk in terms of short-term price fluctuations for BIO.Check SIBN's competition here
CeriBell, Inc. (NASDAQ: CBLL)
BIO vs CBLL Comparison August 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 9.6B. In comparison, CBLL has a market cap of 808.6M. Regarding current trading prices, BIO is priced at $356.25 on the NYSE, while CBLL trades at $21.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of 38.40, whereas CBLL's P/E ratio is -13.07. In terms of profitability, BIO's ROE is +0.03%, compared to CBLL's ROE of -0.45%. Regarding short-term risk, BIO is less volatile compared to CBLL. This indicates lower risk in terms of short-term price fluctuations for BIO.Check CBLL's competition here
Beta Bionics, Inc. (NASDAQ: BBNX)
BIO vs BBNX Comparison August 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 9.6B. In comparison, BBNX has a market cap of 792.7M. Regarding current trading prices, BIO is priced at $356.25 on the NYSE, while BBNX trades at $17.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of 38.40, whereas BBNX's P/E ratio is -11.67. In terms of profitability, BIO's ROE is +0.03%, compared to BBNX's ROE of -0.26%. Regarding short-term risk, BIO is less volatile compared to BBNX. This indicates lower risk in terms of short-term price fluctuations for BIO.Check BBNX's competition here
Varex Imaging Corporation (NASDAQ: VREX)
BIO vs VREX Comparison August 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 9.6B. In comparison, VREX has a market cap of 782.2M. Regarding current trading prices, BIO is priced at $356.25 on the NYSE, while VREX trades at $18.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of 38.40, whereas VREX's P/E ratio is 19.56. In terms of profitability, BIO's ROE is +0.03%, compared to VREX's ROE of +0.05%. Regarding short-term risk, BIO is more volatile compared to VREX. This indicates higher risk in terms of short-term price fluctuations for BIO.Check VREX's competition here
AdaptHealth Corp. (NASDAQ: AHCO)
BIO vs AHCO Comparison August 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 9.6B. In comparison, AHCO has a market cap of 768.7M. Regarding current trading prices, BIO is priced at $356.25 on the NYSE, while AHCO trades at $5.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of 38.40, whereas AHCO's P/E ratio is 11.53. In terms of profitability, BIO's ROE is +0.03%, compared to AHCO's ROE of -0.15%. Regarding short-term risk, BIO is less volatile compared to AHCO. This indicates lower risk in terms of short-term price fluctuations for BIO.Check AHCO's competition here
SS Innovations International, Inc. (NASDAQ: SSII)
BIO vs SSII Comparison August 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 9.6B. In comparison, SSII has a market cap of 722.5M. Regarding current trading prices, BIO is priced at $356.25 on the NYSE, while SSII trades at $3.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of 38.40, whereas SSII's P/E ratio is -70.41. In terms of profitability, BIO's ROE is +0.03%, compared to SSII's ROE of -0.23%. Regarding short-term risk, BIO is less volatile compared to SSII. This indicates lower risk in terms of short-term price fluctuations for BIO.Check SSII's competition here
OrthoPediatrics Corp. (NASDAQ: KIDS)
BIO vs KIDS Comparison August 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 9.6B. In comparison, KIDS has a market cap of 622.6M. Regarding current trading prices, BIO is priced at $356.25 on the NYSE, while KIDS trades at $24.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of 38.40, whereas KIDS's P/E ratio is -20.54. In terms of profitability, BIO's ROE is +0.03%, compared to KIDS's ROE of -0.12%. Regarding short-term risk, BIO is less volatile compared to KIDS. This indicates lower risk in terms of short-term price fluctuations for BIO.Check KIDS's competition here
Surmodics, Inc. (NASDAQ: SRDX)
BIO vs SRDX Comparison August 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 9.6B. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, BIO is priced at $356.25 on the NYSE, while SRDX trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of 38.40, whereas SRDX's P/E ratio is -34.66. In terms of profitability, BIO's ROE is +0.03%, compared to SRDX's ROE of -0.10%. Regarding short-term risk, BIO is more volatile compared to SRDX. This indicates higher risk in terms of short-term price fluctuations for BIO.Check SRDX's competition here
Cytek Biosciences, Inc. (NASDAQ: CTKB)
BIO vs CTKB Comparison August 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 9.6B. In comparison, CTKB has a market cap of 612.1M. Regarding current trading prices, BIO is priced at $356.25 on the NYSE, while CTKB trades at $4.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of 38.40, whereas CTKB's P/E ratio is -25.11. In terms of profitability, BIO's ROE is +0.03%, compared to CTKB's ROE of -0.24%. Regarding short-term risk, BIO is less volatile compared to CTKB. This indicates lower risk in terms of short-term price fluctuations for BIO.Check CTKB's competition here
Delcath Systems, Inc. (NASDAQ: DCTH)
BIO vs DCTH Comparison August 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 9.6B. In comparison, DCTH has a market cap of 594.5M. Regarding current trading prices, BIO is priced at $356.25 on the NYSE, while DCTH trades at $17.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of 38.40, whereas DCTH's P/E ratio is 1722.00. In terms of profitability, BIO's ROE is +0.03%, compared to DCTH's ROE of +0.00%. Regarding short-term risk, BIO is less volatile compared to DCTH. This indicates lower risk in terms of short-term price fluctuations for BIO.Check DCTH's competition here
BrainsWay Ltd. (NASDAQ: BWAY)
BIO vs BWAY Comparison August 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 9.6B. In comparison, BWAY has a market cap of 587.6M. Regarding current trading prices, BIO is priced at $356.25 on the NYSE, while BWAY trades at $14.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of 38.40, whereas BWAY's P/E ratio is 38.06. In terms of profitability, BIO's ROE is +0.03%, compared to BWAY's ROE of +0.12%. Regarding short-term risk, BIO is less volatile compared to BWAY. This indicates lower risk in terms of short-term price fluctuations for BIO.Check BWAY's competition here
Apollo Endosurgery, Inc. (NASDAQ: APEN)
BIO vs APEN Comparison August 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 9.6B. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, BIO is priced at $356.25 on the NYSE, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of 38.40, whereas APEN's P/E ratio is -9.43. In terms of profitability, BIO's ROE is +0.03%, compared to APEN's ROE of -0.85%. Regarding short-term risk, BIO is more volatile compared to APEN. This indicates higher risk in terms of short-term price fluctuations for BIO.Check APEN's competition here
Tactile Systems Technology, Inc. (NASDAQ: TCMD)
BIO vs TCMD Comparison August 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 9.6B. In comparison, TCMD has a market cap of 544.7M. Regarding current trading prices, BIO is priced at $356.25 on the NYSE, while TCMD trades at $24.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of 38.40, whereas TCMD's P/E ratio is 27.44. In terms of profitability, BIO's ROE is +0.03%, compared to TCMD's ROE of +0.11%. Regarding short-term risk, BIO is less volatile compared to TCMD. This indicates lower risk in terms of short-term price fluctuations for BIO.Check TCMD's competition here
ZimVie Inc. (NASDAQ: ZIMV)
BIO vs ZIMV Comparison August 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 9.6B. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, BIO is priced at $356.25 on the NYSE, while ZIMV trades at $18.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of 38.40, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, BIO's ROE is +0.03%, compared to ZIMV's ROE of -0.01%. Regarding short-term risk, BIO is more volatile compared to ZIMV. This indicates higher risk in terms of short-term price fluctuations for BIO.Check ZIMV's competition here
Cerus Corporation (NASDAQ: CERS)
BIO vs CERS Comparison August 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 9.6B. In comparison, CERS has a market cap of 516.9M. Regarding current trading prices, BIO is priced at $356.25 on the NYSE, while CERS trades at $2.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of 38.40, whereas CERS's P/E ratio is -51.20. In terms of profitability, BIO's ROE is +0.03%, compared to CERS's ROE of -0.10%. Regarding short-term risk, BIO is less volatile compared to CERS. This indicates lower risk in terms of short-term price fluctuations for BIO.Check CERS's competition here
NeuroPace, Inc. (NASDAQ: NPCE)
BIO vs NPCE Comparison August 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 9.6B. In comparison, NPCE has a market cap of 512.4M. Regarding current trading prices, BIO is priced at $356.25 on the NYSE, while NPCE trades at $15.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of 38.40, whereas NPCE's P/E ratio is -23.12. In terms of profitability, BIO's ROE is +0.03%, compared to NPCE's ROE of -1.21%. Regarding short-term risk, BIO is less volatile compared to NPCE. This indicates lower risk in terms of short-term price fluctuations for BIO.Check NPCE's competition here
ClearPoint Neuro, Inc. (NASDAQ: CLPT)
BIO vs CLPT Comparison August 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 9.6B. In comparison, CLPT has a market cap of 446.8M. Regarding current trading prices, BIO is priced at $356.25 on the NYSE, while CLPT trades at $14.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of 38.40, whereas CLPT's P/E ratio is -12.63. In terms of profitability, BIO's ROE is +0.03%, compared to CLPT's ROE of -1.88%. Regarding short-term risk, BIO is less volatile compared to CLPT. This indicates lower risk in terms of short-term price fluctuations for BIO.Check CLPT's competition here
Sight Sciences, Inc. (NASDAQ: SGHT)
BIO vs SGHT Comparison August 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 9.6B. In comparison, SGHT has a market cap of 421.7M. Regarding current trading prices, BIO is priced at $356.25 on the NYSE, while SGHT trades at $7.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of 38.40, whereas SGHT's P/E ratio is -13.84. In terms of profitability, BIO's ROE is +0.03%, compared to SGHT's ROE of -0.51%. Regarding short-term risk, BIO is less volatile compared to SGHT. This indicates lower risk in terms of short-term price fluctuations for BIO.Check SGHT's competition here
Orthofix Medical Inc. (NASDAQ: OFIX)
BIO vs OFIX Comparison August 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 9.6B. In comparison, OFIX has a market cap of 417.2M. Regarding current trading prices, BIO is priced at $356.25 on the NYSE, while OFIX trades at $10.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of 38.40, whereas OFIX's P/E ratio is -13.48. In terms of profitability, BIO's ROE is +0.03%, compared to OFIX's ROE of -0.14%. Regarding short-term risk, BIO is less volatile compared to OFIX. This indicates lower risk in terms of short-term price fluctuations for BIO.Check OFIX's competition here
Carlsmed, Inc. (NASDAQ: CARL)
BIO vs CARL Comparison August 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 9.6B. In comparison, CARL has a market cap of 373.2M. Regarding current trading prices, BIO is priced at $356.25 on the NYSE, while CARL trades at $13.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of 38.40, whereas CARL's P/E ratio is -9.60. In terms of profitability, BIO's ROE is +0.03%, compared to CARL's ROE of -0.38%. Regarding short-term risk, BIO is less volatile compared to CARL. This indicates lower risk in terms of short-term price fluctuations for BIO.Check CARL's competition here
Picard Medical, Inc. (AMEX: PMI)
BIO vs PMI Comparison August 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 9.6B. In comparison, PMI has a market cap of 368.7M. Regarding current trading prices, BIO is priced at $356.25 on the NYSE, while PMI trades at $3.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of 38.40, whereas PMI's P/E ratio is -2.99. In terms of profitability, BIO's ROE is +0.03%, compared to PMI's ROE of +4.99%. Regarding short-term risk, BIO is less volatile compared to PMI. This indicates lower risk in terms of short-term price fluctuations for BIO.Check PMI's competition here
Perspective Therapeutics, Inc. (AMEX: CATX)
BIO vs CATX Comparison August 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 9.6B. In comparison, CATX has a market cap of 362.1M. Regarding current trading prices, BIO is priced at $356.25 on the NYSE, while CATX trades at $3.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of 38.40, whereas CATX's P/E ratio is -2.25. In terms of profitability, BIO's ROE is +0.03%, compared to CATX's ROE of -0.42%. Regarding short-term risk, BIO is less volatile compared to CATX. This indicates lower risk in terms of short-term price fluctuations for BIO.Check CATX's competition here
Pacific Biosciences of California, Inc. (NASDAQ: PACB)
BIO vs PACB Comparison August 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 9.6B. In comparison, PACB has a market cap of 354.1M. Regarding current trading prices, BIO is priced at $356.25 on the NYSE, while PACB trades at $1.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of 38.40, whereas PACB's P/E ratio is -2.78. In terms of profitability, BIO's ROE is +0.03%, compared to PACB's ROE of -49.62%. Regarding short-term risk, BIO is more volatile compared to PACB. This indicates higher risk in terms of short-term price fluctuations for BIO.Check PACB's competition here
TriSalus Life Sciences, Inc. (NASDAQ: TLSI)
BIO vs TLSI Comparison August 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 9.6B. In comparison, TLSI has a market cap of 353.4M. Regarding current trading prices, BIO is priced at $356.25 on the NYSE, while TLSI trades at $5.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of 38.40, whereas TLSI's P/E ratio is -3.42. In terms of profitability, BIO's ROE is +0.03%, compared to TLSI's ROE of +2.74%. Regarding short-term risk, BIO is less volatile compared to TLSI. This indicates lower risk in terms of short-term price fluctuations for BIO.Check TLSI's competition here
Electromed, Inc. (AMEX: ELMD)
BIO vs ELMD Comparison August 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 9.6B. In comparison, ELMD has a market cap of 350.8M. Regarding current trading prices, BIO is priced at $356.25 on the NYSE, while ELMD trades at $42.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of 38.40, whereas ELMD's P/E ratio is 36.21. In terms of profitability, BIO's ROE is +0.03%, compared to ELMD's ROE of +0.22%. Regarding short-term risk, BIO is less volatile compared to ELMD. This indicates lower risk in terms of short-term price fluctuations for BIO.Check ELMD's competition here
CapsoVision, Inc. (NASDAQ: CV)
BIO vs CV Comparison August 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 9.6B. In comparison, CV has a market cap of 329.8M. Regarding current trading prices, BIO is priced at $356.25 on the NYSE, while CV trades at $6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of 38.40, whereas CV's P/E ratio is -2.64. In terms of profitability, BIO's ROE is +0.03%, compared to CV's ROE of +1.27%. Regarding short-term risk, BIO is less volatile compared to CV. This indicates lower risk in terms of short-term price fluctuations for BIO.Check CV's competition here
Senseonics Holdings, Inc. (NASDAQ: SENS)
BIO vs SENS Comparison August 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 9.6B. In comparison, SENS has a market cap of 328.9M. Regarding current trading prices, BIO is priced at $356.25 on the NYSE, while SENS trades at $7.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of 38.40, whereas SENS's P/E ratio is -3.93. In terms of profitability, BIO's ROE is +0.03%, compared to SENS's ROE of -1.66%. Regarding short-term risk, BIO is less volatile compared to SENS. This indicates lower risk in terms of short-term price fluctuations for BIO.Check SENS's competition here
Semler Scientific, Inc. (NASDAQ: SMLR)
BIO vs SMLR Comparison August 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 9.6B. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, BIO is priced at $356.25 on the NYSE, while SMLR trades at $20.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of 38.40, whereas SMLR's P/E ratio is 3.92. In terms of profitability, BIO's ROE is +0.03%, compared to SMLR's ROE of +0.06%. Regarding short-term risk, BIO is more volatile compared to SMLR. This indicates higher risk in terms of short-term price fluctuations for BIO.Check SMLR's competition here
Treace Medical Concepts, Inc. (NASDAQ: TMCI)
BIO vs TMCI Comparison August 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 9.6B. In comparison, TMCI has a market cap of 307.5M. Regarding current trading prices, BIO is priced at $356.25 on the NYSE, while TMCI trades at $4.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of 38.40, whereas TMCI's P/E ratio is -5.04. In terms of profitability, BIO's ROE is +0.03%, compared to TMCI's ROE of -0.74%. Regarding short-term risk, BIO is less volatile compared to TMCI. This indicates lower risk in terms of short-term price fluctuations for BIO.Check TMCI's competition here
RxSight, Inc. (NASDAQ: RXST)
BIO vs RXST Comparison August 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 9.6B. In comparison, RXST has a market cap of 291.4M. Regarding current trading prices, BIO is priced at $356.25 on the NYSE, while RXST trades at $7.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of 38.40, whereas RXST's P/E ratio is -7.57. In terms of profitability, BIO's ROE is +0.03%, compared to RXST's ROE of -0.17%. Regarding short-term risk, BIO is less volatile compared to RXST. This indicates lower risk in terms of short-term price fluctuations for BIO.Check RXST's competition here
Anika Therapeutics, Inc. (NASDAQ: ANIK)
BIO vs ANIK Comparison August 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 9.6B. In comparison, ANIK has a market cap of 284.1M. Regarding current trading prices, BIO is priced at $356.25 on the NYSE, while ANIK trades at $21.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of 38.40, whereas ANIK's P/E ratio is 43.33. In terms of profitability, BIO's ROE is +0.03%, compared to ANIK's ROE of -0.03%. Regarding short-term risk, BIO is less volatile compared to ANIK. This indicates lower risk in terms of short-term price fluctuations for BIO.Check ANIK's competition here
Profound Medical Corp. (NASDAQ: PROF)
BIO vs PROF Comparison August 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 9.6B. In comparison, PROF has a market cap of 253.6M. Regarding current trading prices, BIO is priced at $356.25 on the NYSE, while PROF trades at $6.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of 38.40, whereas PROF's P/E ratio is -5.63. In terms of profitability, BIO's ROE is +0.03%, compared to PROF's ROE of -0.56%. Regarding short-term risk, BIO is less volatile compared to PROF. This indicates lower risk in terms of short-term price fluctuations for BIO.Check PROF's competition here
Monogram Orthopaedics, Inc. (NASDAQ: MGRM)
BIO vs MGRM Comparison August 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 9.6B. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, BIO is priced at $356.25 on the NYSE, while MGRM trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of 38.40, whereas MGRM's P/E ratio is -12.00. In terms of profitability, BIO's ROE is +0.03%, compared to MGRM's ROE of -0.85%. Regarding short-term risk, BIO is more volatile compared to MGRM. This indicates higher risk in terms of short-term price fluctuations for BIO.Check MGRM's competition here
EDAP TMS S.A. American Depositary Shares (NASDAQ: FOCL)
BIO vs FOCL Comparison August 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 9.6B. In comparison, FOCL has a market cap of 225.3M. Regarding current trading prices, BIO is priced at $356.25 on the NYSE, while FOCL trades at $6.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of 38.40, whereas FOCL's P/E ratio is -7.33. In terms of profitability, BIO's ROE is +0.03%, compared to FOCL's ROE of -1.38%. Regarding short-term risk, BIO is less volatile compared to FOCL. This indicates lower risk in terms of short-term price fluctuations for BIO.Check FOCL's competition here
Nevro Corp. (NYSE: NVRO)
BIO vs NVRO Comparison August 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 9.6B. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, BIO is priced at $356.25 on the NYSE, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of 38.40, whereas NVRO's P/E ratio is -1.91. In terms of profitability, BIO's ROE is +0.03%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, BIO is more volatile compared to NVRO. This indicates higher risk in terms of short-term price fluctuations for BIO.Check NVRO's competition here
Neuronetics, Inc. (NASDAQ: STIM)
BIO vs STIM Comparison August 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 9.6B. In comparison, STIM has a market cap of 222M. Regarding current trading prices, BIO is priced at $356.25 on the NYSE, while STIM trades at $3.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of 38.40, whereas STIM's P/E ratio is -5.91. In terms of profitability, BIO's ROE is +0.03%, compared to STIM's ROE of -1.51%. Regarding short-term risk, BIO is less volatile compared to STIM. This indicates lower risk in terms of short-term price fluctuations for BIO.Check STIM's competition here
Avita Medical Inc. (NASDAQ: RCEL)
BIO vs RCEL Comparison August 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 9.6B. In comparison, RCEL has a market cap of 203.7M. Regarding current trading prices, BIO is priced at $356.25 on the NYSE, while RCEL trades at $8.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of 38.40, whereas RCEL's P/E ratio is -5.22. In terms of profitability, BIO's ROE is +0.03%, compared to RCEL's ROE of +2.32%. Regarding short-term risk, BIO is less volatile compared to RCEL. This indicates lower risk in terms of short-term price fluctuations for BIO.Check RCEL's competition here
BioSig Technologies, Inc. (NASDAQ: BSGM)
BIO vs BSGM Comparison August 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 9.6B. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, BIO is priced at $356.25 on the NYSE, while BSGM trades at $6.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of 38.40, whereas BSGM's P/E ratio is -5.81. In terms of profitability, BIO's ROE is +0.03%, compared to BSGM's ROE of +15.26%. Regarding short-term risk, BIO is less volatile compared to BSGM. This indicates lower risk in terms of short-term price fluctuations for BIO.Check BSGM's competition here
Lucid Diagnostics Inc. (NASDAQ: LUCD)
BIO vs LUCD Comparison August 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 9.6B. In comparison, LUCD has a market cap of 183.4M. Regarding current trading prices, BIO is priced at $356.25 on the NYSE, while LUCD trades at $0.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of 38.40, whereas LUCD's P/E ratio is -2.60. In terms of profitability, BIO's ROE is +0.03%, compared to LUCD's ROE of -3.70%. Regarding short-term risk, BIO is less volatile compared to LUCD. This indicates lower risk in terms of short-term price fluctuations for BIO.Check LUCD's competition here
Xylo Technologies Ltd. (NASDAQ: MDGS)
BIO vs MDGS Comparison August 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 9.6B. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, BIO is priced at $356.25 on the NYSE, while MDGS trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of 38.40, whereas MDGS's P/E ratio is -0.27. In terms of profitability, BIO's ROE is +0.03%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, BIO is less volatile compared to MDGS. This indicates lower risk in terms of short-term price fluctuations for BIO.Check MDGS's competition here
Quipt Home Medical Corp. (NASDAQ: QIPT)
BIO vs QIPT Comparison August 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 9.6B. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, BIO is priced at $356.25 on the NYSE, while QIPT trades at $3.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of 38.40, whereas QIPT's P/E ratio is -15.87. In terms of profitability, BIO's ROE is +0.03%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, BIO is more volatile compared to QIPT. This indicates higher risk in terms of short-term price fluctuations for BIO.Check QIPT's competition here
Inogen, Inc. (NASDAQ: INGN)
BIO vs INGN Comparison August 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 9.6B. In comparison, INGN has a market cap of 159.7M. Regarding current trading prices, BIO is priced at $356.25 on the NYSE, while INGN trades at $5.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of 38.40, whereas INGN's P/E ratio is -6.48. In terms of profitability, BIO's ROE is +0.03%, compared to INGN's ROE of -0.13%. Regarding short-term risk, BIO is less volatile compared to INGN. This indicates lower risk in terms of short-term price fluctuations for BIO.Check INGN's competition here
Quanterix Corporation (NASDAQ: QTRX)
BIO vs QTRX Comparison August 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 9.6B. In comparison, QTRX has a market cap of 123.7M. Regarding current trading prices, BIO is priced at $356.25 on the NYSE, while QTRX trades at $2.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of 38.40, whereas QTRX's P/E ratio is -1.64. In terms of profitability, BIO's ROE is +0.03%, compared to QTRX's ROE of -0.44%. Regarding short-term risk, BIO is less volatile compared to QTRX. This indicates lower risk in terms of short-term price fluctuations for BIO.Check QTRX's competition here
iCAD, Inc. (NASDAQ: ICAD)
BIO vs ICAD Comparison August 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 9.6B. In comparison, ICAD has a market cap of 106.3M. Regarding current trading prices, BIO is priced at $356.25 on the NYSE, while ICAD trades at $3.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of 38.40, whereas ICAD's P/E ratio is -20.37. In terms of profitability, BIO's ROE is +0.03%, compared to ICAD's ROE of -0.18%. Regarding short-term risk, BIO is more volatile compared to ICAD. This indicates higher risk in terms of short-term price fluctuations for BIO.Check ICAD's competition here
Solana Company (NASDAQ: HSDT)
BIO vs HSDT Comparison August 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 9.6B. In comparison, HSDT has a market cap of 101.6M. Regarding current trading prices, BIO is priced at $356.25 on the NYSE, while HSDT trades at $1.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of 38.40, whereas HSDT's P/E ratio is -0.02. In terms of profitability, BIO's ROE is +0.03%, compared to HSDT's ROE of -1.55%. Regarding short-term risk, BIO is less volatile compared to HSDT. This indicates lower risk in terms of short-term price fluctuations for BIO.Check HSDT's competition here
Owlet, Inc. (NYSE: OWLT)
BIO vs OWLT Comparison August 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 9.6B. In comparison, OWLT has a market cap of 98.4M. Regarding current trading prices, BIO is priced at $356.25 on the NYSE, while OWLT trades at $5.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of 38.40, whereas OWLT's P/E ratio is -38.86. In terms of profitability, BIO's ROE is +0.03%, compared to OWLT's ROE of +11.36%. Regarding short-term risk, BIO is less volatile compared to OWLT. This indicates lower risk in terms of short-term price fluctuations for BIO.Check OWLT's competition here
Hancock Jaffe Laboratories (NASDAQ: HJLI)
BIO vs HJLI Comparison August 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO stands at 9.6B. In comparison, HJLI has a market cap of 98.3M. Regarding current trading prices, BIO is priced at $356.25 on the NYSE, while HJLI trades at $10.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO currently has a P/E ratio of 38.40, whereas HJLI's P/E ratio is N/A. In terms of profitability, BIO's ROE is +0.03%, compared to HJLI's ROE of -0.62%. Regarding short-term risk, BIO is less volatile compared to HJLI. This indicates lower risk in terms of short-term price fluctuations for BIO.Check HJLI's competition here